Monem E A, Al-Bahrani B, Mehdi I, Nada A
Essam Abdul Monem, Department of Medical Oncology, National Cancer Center, Royal Hospital, Muscat, Sultanate of Oman. Tel: 968 92575280 Fax: 968 24627045 E-mail:
Gulf J Oncolog. 2013 Jul;1(14):52-6.
Rituximab, a chimeric monoclonal antibody (MoAb) targeting CD20 has been widely used in the management of B-cell lympho-proliferative disorders.(1-3) The usual recommended schedule of regular administration over 3 to 4 hours requires considerable healthcare resources and oftentimes inconvenient for patients. Literature shows the availability of published reports proving the safety and feasibility of rapid infusion of rituximab. This study explored the safety and tolerability of rituximab infusion over a shorter total infusion time. A total of 24 patients diagnosed with CD20+ Non-Hodgkin's lymphoma and planned to receive rituximab at a dose of 375mg/m2 in combination with standard chemotherapy regimens were included in the study from January 2009 to December 2009. The administration of first rituximab dose was unaltered and given as per standard practice of 3-4 hours infusion. The second and subsequent doses were delivered over a total infusion time of only 90 minutes (20% of dose in the first 30 minutes, remaining 80% over the next 60 minutes). These patients, aged between 15 and 79 years, received a total of 152 rituximab infusions with an average of 6.33 (+/-2.37) infusions per patient. Grade 1 infusion related toxicity was reported in 5 infusions (3.2%), and there were no acute reactions or G3/4 toxicity in any infusion episode. A rapid infusion of rituximab is well tolerated, feasible and safe when administered as second and subsequent infusions in the course of therapy for those who tolerate the first dose without significant infusion related toxicity. This shortened infusion method results in a substantial reduction in resource utilization. Our institution has now adopted this as a routine practice.
Rituximab, Short infusion, Oman.
利妥昔单抗是一种靶向CD20的嵌合单克隆抗体（MoAb），已广泛用于B细胞淋巴增殖性疾病的治疗。（1 - 3）通常推荐的在3至4小时内常规给药的方案需要大量医疗资源，而且对患者来说常常不方便。文献表明，已有发表的报告证明了利妥昔单抗快速输注的安全性和可行性。本研究探讨了在较短的总输注时间内输注利妥昔单抗的安全性和耐受性。2009年1月至2009年12月，共有24例被诊断为CD20 +非霍奇金淋巴瘤且计划接受375mg/m2剂量利妥昔单抗联合标准化疗方案的患者纳入本研究。首次利妥昔单抗剂量的给药未改变，按照3 - 4小时输注的标准做法进行。第二次及后续剂量在仅90分钟的总输注时间内给药（前30分钟给予20%的剂量，接下来60分钟给予其余80%的剂量）。这些患者年龄在15至79岁之间，共接受了152次利妥昔单抗输注，平均每位患者6.33（±2.37）次输注。5次输注（3.2%）报告了1级输注相关毒性，在任何输注过程中均未出现急性反应或3/4级毒性。对于那些在首次剂量输注时没有明显输注相关毒性的患者，在治疗过程中作为第二次及后续输注时，快速输注利妥昔单抗耐受性良好、可行且安全。这种缩短的输注方法可大幅减少资源利用。我们机构现在已将此作为常规做法。
利妥昔单抗；短时间输注；阿曼
